IngredientsCoumarin (2H-1-benzopyran-2-one) is a plant-derived natural product belonging to a broad family of structurally related secondary metabolites. Coumarin belongs to the benzopyrone chemical class, specifically a lactone of o-hydroxycinnamic acid. Coumarins consist of a large class of phenolic substances found in plants, made of fused benzene and α-pyrone rings. Its molecular formula is C₉H₆O₂, and coumarin is a colorless crystalline solid with a sweet odor resembling the scent of vanilla and a bitter taste. Coumarin is responsible for the smell of fresh-cut grass.
It is lipophilic (fat-soluble) but shows some solubility in ethanol-based extracts. More than 1,300 coumarins have been identified as secondary metabolites from plants, bacteria, and fungi. Coumarin is found in many plants, where it may serve as a chemical defense against predators.
It is important to note an often-confused distinction: while coumarin is not itself an anticoagulant, its 3-alkyl-4-hydroxy derivatives, such as the fungal metabolite dicoumarol, inhibit the synthesis of vitamin K, a key component in blood clotting. Unlike coumadin (or warfarin), coumarin has no anticoagulant activity and is not used clinically as an anticoagulant or as a rodenticide.
According to the different substituents, coumarins can be divided into five classes: simple coumarins, pyranocoumarins, furocoumarins, dicoumarin, and isocoumarin. A more detailed classification used in the literature also includes isocoumarins, biscoumarins, and phenylcoumarins. The families Apiaceae, Asteraceae, and Rutaceae are the three major plant sources of coumarins; generally, these plant secondary metabolites may be classified into simple, simple prenylated, simple geranylated, furano, pyrano, sesquiterpenyl, and oligomeric coumarins.
The initial member of this group, coumarin (2H-1-benzopyran-2-one), a fragrant colorless compound, was first isolated from the Tonka bean (Dipteryx odorata, family Fabaceae) in 1820. The name coumarin comes from a French term for the tonka bean, coumarou. More precisely, coumarin was first isolated from tonka beans in 1820 by A. Vogel of Munich, who initially mistook it for benzoic acid. Also in 1820, Nicholas Jean Baptiste Gaston Guibourt of France independently isolated coumarin, but he realized that it was not benzoic acid. Its synthesis in 1868 by the English chemist Sir William Henry Perkin was the first application of a general chemical reaction now known by his name.
Most coumarins occur in higher plants, with the richest sources being the Rutaceae and Umbelliferae. Although distributed throughout all parts of the plant, coumarins occur at the highest levels in the fruits, followed by the roots, stems, and leaves. Environmental conditions and seasonal changes can influence their occurrence in diverse parts of the plant.
The most significant dietary sources include:
Coumarins are usually found in plants in their free forms, as well as glucosides. Plants concentrate coumarin in their seeds, bark, and roots as a defense compound against pests.
Coumarin reaches humans through several routes: as a naturally occurring component of food spices and condiments (primarily cassia cinnamon); as an ingredient in cinnamon-based dietary supplements in capsule or powder form; through cosmetic products; and historically as an isolated pharmaceutical agent. Coumarin is used in the cosmetics industry as a fragrance in perfumes, shower gels, lotions, or deodorants. The substance can be absorbed relatively easily through the skin and can thus lead to increased coumarin uptake when used regularly, especially in leave-on products such as perfumes. Coumarin is widely used in perfumes, hand soaps, detergents, and lotions at concentrations from 0.01% to 2.4%.
Synthetic coumarin can also be produced industrially. Coumarin can be obtained synthetically and is commonly used in food and cosmetics. In terms of its industrial and fragrance uses, coumarin is mainly used as a fragrance and flavoring agent in perfumery and in the tobacco industry. It is also used to flavor drinks and confectionery (including chewing gum), and is used in the kitchen (in the form of wilted woodruff leaves) to flavor May punch, for example.
Coumarins are a diverse group of naturally occurring compounds long recognized in traditional medicine for their broad therapeutic potential. This history spans ancient healing traditions—such as Ayurveda, Traditional Chinese Medicine, and various indigenous systems. Widely distributed in medicinal plants, coumarins have historically been used to treat inflammation, microbial infections, and oxidative stress-related conditions.
Most of these plants are well known for their uses and are present in traditional medicine systems: Ayurveda Medicine, Traditional Chinese Medicine, and Unani Medicine, or in other recent cultures.
In ancient European herbalism, coumarin-rich plants like sweet clover (Melilotus officinalis) were commonly used for their calming and soothing properties. Folk medicine practitioners employed these herbs as remedies for insomnia, anxiety, and muscle tension, often preparing infusions or poultices to support relaxation and alleviate pain. Additionally, coumarin-containing plants were utilized to promote healthy circulation, with external applications used to ease bruises and swellings due to their mild anti-inflammatory effects.
In medieval Europe, meadowsweet and woodruff flavored wines and cordials for spring festivals — these plants are also coumarin sources. Sweet woodruff was used to flavor the traditional German Maiwein (May wine). In hay flower preparations, where the fine parts of the hay are processed, the effluent coumarin is used as a traditional remedy.
In particular, preparations from the environment of traditional Asian medicine often use cinnamon varieties rich in coumarin. Thus, these products can lead to an unintentional, undesirable coumarin intake. Cinnamon is one of the oldest spices in the world and is obtained from the dried bark of the cinnamon tree. Especially the bark and leaves of the cinnamon tree are used in many foods and refreshments, but also in pharmaceutical preparations as well as in folk medicine.
The tonka bean (Dipteryx odorata), native to Guyana and Venezuela, was the original source from which coumarin was first isolated scientifically. Some plants bearing coumarin-related compounds are reported in folk medicine as traditional remedies for the treatment of respiratory diseases. Coumarins are also present in several species belonging to different botanical families, widespread in the northeastern region of Brazil.
Colonial Americans learned from Native Americans to brew teas from sweet clover leaves to ease bruising and swelling, intuitively harnessing coumarin's effect on circulation.
Across these traditions, the primary modes of preparation included aqueous infusions (teas) of dried coumarin-rich plant material, poultices of fresh or dried herbs applied externally to bruises and swellings, wine and alcoholic beverage infusions, aromatic preparations and fumigants, and spiced decoctions as digestive aids. These uses predate the isolation of coumarin as a specific chemical entity in 1820 and reflect the pharmacological action of coumarin-containing plants as a whole, rather than isolated coumarin.
Coumarins (2H-1-benzopyran-2-one) consist of a large class of phenolic substances found in plants and are made of fused benzene and α-pyrone rings. Coumarin is characterized by a simple structure, benzopyrone, on which there are multiple substitution sites. The structure of coumarin determines its many biological pharmacological activities, and the heterocyclic structure of coumarin is easy to bind to a variety of target proteins. The 2H-chromen-2-one ring can interact with different biological antigens because of its aromatic, planar, and lipophilic character.
Notable individual coumarin-class compounds of pharmacological relevance include:
A narrative review aimed to comprehensively summarize the current knowledge regarding coumarin's pharmacological effects in alleviating inflammatory conditions by analyzing preclinical and clinical studies. The review focuses on elucidating the mechanisms through which coumarin exerts its anti-inflammatory effects, including its antioxidant activity, inhibiting pro-inflammatory cytokine production, and modulation of immune cell functions. Coumarins also reduce edema and inflammation by inhibiting the prostaglandins biosynthesis. Hydroxyl aromatic substituted derivatives such as 5-hydroxycoumarin or vicinal dihydroxy coumarins have also been found to be potent anti-inflammatory agents.
Coumarins are vitamin K antagonists that produce their anticoagulant effect by interfering with the cyclic interconversion of vitamin K and its 2,3 epoxide (vitamin K epoxide). Vitamin K is a cofactor for the posttranslational carboxylation of glutamate residues on vitamin K-dependent proteins. These coagulation factors (factors II, VII, IX, and X) require γ-carboxylation for their biological activity. This mechanism applies principally to coumarin derivatives such as dicoumarol and warfarin, not to coumarin itself.
Most of these effects can be attributed to the free radical scavenging effects of coumarins. Coumarins such as umbelliferone, esculetin, and quercetin show antioxidant properties and protect the cellular DNA from oxidative damage.
In particular, coumarins have very significant anti-tumor abilities and a variety of anti-tumor mechanisms, including inhibition of carbonic anhydrase, targeting PI3K/Akt/mTOR signaling pathways, inducing cell apoptosis protein activation, inhibition of tumor multidrug resistance, inhibition of microtubule polymerization, regulating the reactive oxygen species, and inhibition of tumor angiogenesis.
α-Glucosidase is an intestinal enzyme that breaks down carbohydrates into glucose, contributing to postprandial hyperglycemia in type 2 diabetes. Inhibition of this enzyme slows glucose absorption, reducing blood sugar spikes after meals. This mechanism is used by drugs like acarbose. Natural coumarins also exhibit α-glucosidase inhibitory activity and thus may offer effective alternatives with fewer side effects.
Coumarin and related drugs have been reported to reduce lymphedema, possibly through stimulation of proteolysis by tissue macrophages. This macrophage-activating mechanism is considered the primary proposed basis for coumarin's use in treating lymphedema at pharmacological doses.
Sampling human plasma after oral administration of coumarin showed that, although almost completely absorbed, only 2 to 6% reaches the systemic circulation. This reflects extensive first-pass metabolism in the liver. Several previous pharmacokinetic studies of coumarin have been performed in humans, which revealed extensive first-pass metabolism of the compound. 7-Hydroxycoumarin (7-HC) and its glucuronide (7-HC-G) are the main metabolites formed in humans, and via this route, 80 to 90% of the absorbed coumarin is excreted into urine, mainly as 7-HC-G.
The enzyme responsible for the primary metabolic pathway in humans is CYP2A6. Coumarin 7-hydroxylation is catalyzed by a high-affinity CYP2A6 enzyme in human liver microsomes. CYP2A6 is the only enzyme catalyzing this reaction, and consequently the formation of 7-hydroxycoumarin can be used as an in vitro and in vivo probe for CYP2A6. CYP2A6 constitutes 5–10% of the total microsomal CYPs of human liver. This enzyme is predominantly expressed in the liver and is responsible for the clearance of many drugs and environmental chemicals.
The human metabolic pathway is fundamentally different from that of rodents, which has important toxicological implications. It is believed that most humans possess a major pathway for the metabolism of coumarin (the 7-hydroxycoumarin pathway) that differs from that in rats (the 3,4-coumarin epoxidation pathway), in which a reactive epoxide is formed. The 3,4-coumarin epoxide route has been linked to the hepatotoxicity and carcinogenic effects of coumarin observed in long-term studies in rats and mice.
Detoxification of coumarin through 7-hydroxylation may vary among individuals due to genetic polymorphisms in CYP2A6 enzyme. In addition, the CYP1A2- and CYP2E1-mediated activation of coumarin can fluctuate as a result of induction caused by environmental factors. Individuals with certain genetic variations, particularly in the CYP2A6 enzyme, may have a reduced capacity to metabolize coumarin, increasing their susceptibility to its hepatotoxic effects.
The most extensively studied human-use application of isolated coumarin at pharmacological doses is the treatment of lymphedema, particularly post-breast-cancer lymphedema.
Coumarin is used as a pharmaceutical for the treatment of high-protein lymphedema and for improved venous circulation, and has been in clinical trials as an antineoplastic.
Earlier studies produced promising results. In addition to findings that it decreases the pain and discomfort caused by lymphedema, coumarin has been reported to reduce the incidence of cellulitis or lymphangitis and to soften slowly the brawny edema that is often found in conjunction with lymphedema. A double-blind, crossover trial by Casley-Smith et al. (1993) involving 31 women with postmastectomy lymphedema and 21 men and women with leg lymphedema reported coumarin to be more effective than placebo in reducing the volume of edema fluid in the arm, in reducing skin temperature, and in increasing the softness of the limb tissue.
A randomized, double-blind, parallel-group study compared the clinical efficacy of two doses in 77 women aged 35–65 with upper-limb lymphedema secondary to surgery and irradiation for breast cancer. In a randomized, double-blind, parallel group study comparing coumarin 90 mg/day (Group A) with 135 mg/day (Group B) in 77 women with lymphedema of the upper limb, the volume of arm lymphedema decreased (14.9% in Group A and 13.2% in Group B), the overall clinical score improved in both groups, and the overall efficacy of coumarin was similarly good or excellent (71.9% in Group A and 68.6% in Group B). No difference was found between the apparent benefits of coumarin at 90 mg/day compared with 135 mg/day.
However, a larger and more rigorous trial from the Mayo Clinic challenged these findings. A study of 140 women with chronic lymphedema of the ipsilateral arm after treatment for breast cancer received 200 mg of oral coumarin or placebo twice daily for six months, then the other treatment for the following six months. After six months, only 15 percent of the women in the coumarin group and 10 percent of those in the placebo group reported that the study medication had helped a moderate or large amount (P=0.19). Coumarin was well tolerated, except that it resulted in serologic evidence of liver toxicity in 6 percent of the women. Conclusions: Coumarin is not effective therapy for women who have lymphedema of the arm after treatment for breast cancer.
A Cochrane review and related systematic analyses have been cautious. It is not possible to draw conclusions about the effectiveness of benzopyrones in reducing limb volume, pain, or discomfort in lymphedematous limbs from these trials. A subsequent pharmacogenomics perspective noted that although there remains some significant controversy regarding the use and benefits of coumarin (5,6-benzo-alpha-pyrone), targeted, appropriate, and monitored use of the drug does have a significant role in the treatment of lymphedemas.
Evidence strength: Mixed. Positive signals from smaller earlier trials; a well-powered randomized controlled trial found no significant benefit and documented liver toxicity in 6% of participants. The Cochrane review reached no definitive conclusion. Overall clinical evidence is insufficient to support a recommendation.
Coumarin, a naturally occurring compound found in various plants, has a rich history of use in traditional medicine. Recent research has highlighted its anti-inflammatory properties, positioning it as a promising candidate for treating inflammatory disorders such as rheumatoid arthritis, asthma, and inflammatory bowel disease.
Mechanistic evidence has been developed largely through preclinical models. Esculetin (a coumarin derivative) exhibited anti-inflammatory activity in rat colitis induced by trinitrobenzenesulfonic acid. The anti-inflammatory potential has been linked to inhibition of prostaglandin biosynthesis and cytokine modulation.
Evidence strength: Predominantly preclinical (in vitro and animal). Well-characterized mechanisms, but robust human clinical trial data for isolated coumarin as an anti-inflammatory agent are lacking. This area remains investigational.
Coumarin has been studied as a potential antineoplastic agent, both as isolated coumarin and in combination with other treatments.
Preclinical studies suggest that certain coumarin derivatives enhance immune responses by modulating macrophage polarization and T-cell activation. These findings align with nanoparticle-based coumarin formulations, which improve drug bioavailability while boosting immune-mediated tumor suppression. Moreover, pre-treatment with hydroxylated coumarins has been shown to increase the efficacy of platinum-based chemotherapy in lung and ovarian cancer models, suggesting a role in chemosensitization.
Numerous in vitro and in vivo experiments proved coumarins are indeed a kind of potential new antitumor drugs, which have selective cytotoxicity and diverse anti-tumor mechanisms, but there are still problems that most of these studies are not in-depth, lack in vivo experiments, and low solubility in water limits bioavailability.
Higher doses of coumarin are found to be hepatotoxic; however, they exhibit beneficial effects by reducing the risk of cancer and other neuronal and cardiovascular ailments.
Evidence strength: Primarily in vitro and animal model data. Clinical trials in humans are limited; the translation from preclinical to clinical antitumor activity remains unproven. This is an area of active research but not established clinical practice.
Natural coumarins also exhibit α-glucosidase inhibitory activity and thus may offer effective alternatives with fewer side effects. This enzyme inhibition would, in principle, reduce postprandial blood glucose elevations — the same mechanism exploited by the diabetes drug acarbose. Natural coumarins demonstrated antihyperglycemic activity among their broad spectrum of pharmacological activities in laboratory studies.
Evidence strength: Preliminary — primarily in vitro enzyme inhibition assays and animal studies. No robust, dedicated human clinical trials on isolated coumarin for diabetes management have been identified in peer-reviewed literature.
Coumarin hybrids exhibit promising antimicrobial activity, particularly against S. aureus and C. albicans. The structure-activity relationship (SAR) reveals that halogenation, bulky aromatics, nitro, and hydroxyl groups enhance the interaction of the coumarin rings with amino acid residues.
Evidence strength: In vitro only. No human clinical trial data are available for coumarin as a standalone antimicrobial agent. Significant pharmacological interest exists, particularly in drug-resistant pathogen research.
Esculetin (a coumarin derivative) exhibited neuroprotective effects on cerebral ischemia/reperfusion injury in a middle cerebral artery occlusion model in mice. Natural coumarins demonstrated neuroprotective and anticonvulsant activity across laboratory models.
Evidence strength: Entirely preclinical at present. No human data are available.
Pharmacologically described actions attributed to coumarin-class compounds include lymphokinetic, antiphlogistic, antiexudative, anti-edematous, vasodilatory, and bronchospasmolytic effects. These effects provide a rationale for traditional use in conditions associated with venous insufficiency and sluggish circulation.
Evidence strength: Limited human data, mostly from older lymphedema studies (see Section 5.1). No large, well-powered randomized controlled trials specifically targeting cardiovascular endpoints with isolated coumarin supplements have been identified.
The following dosages are reported from clinical studies and should not be interpreted as recommended doses:
There are very few studies on the bioavailability of coumarins; therefore, further investigations are needed to study the bioavailability of different coumarins.
Natural coumarins have demonstrated a wide spectrum of pharmacological activities, including anti-inflammatory, anticoagulant, anticancer, antibacterial, antimalarial, casein kinase-2 (CK2) inhibitory, antifungal, antiviral, Alzheimer's disease inhibition, neuroprotective, anticonvulsant, antihypertensive, and phytoalexin properties.
The primary body systems associated with coumarin activity in the scientific and clinical literature include:
Coumarin was banned as a food additive in the United States in 1954, largely because of hepatotoxicity results in rodents. Coumarin is currently listed by the FDA among "Substances Generally Prohibited From Direct Addition or Use as Human Food," according to 21 CFR 189.130, but some natural additives containing coumarin, such as the flavorant sweet woodruff, are allowed "in alcoholic beverages only" under 21 CFR 172.510.
In the European Union, the presence of coumarins in food is regulated by Decision No 1334/2008 of the European Parliament and Council, which states that coumarin cannot be added to food as an additive. However, Annex III stipulates that coumarin may be allowed in specific foods prepared with cinnamon as a flavor, with maximum admitted levels (e.g., 50 mg/kg for traditional bakery products and 5 mg/kg for desserts).
In Australia, coumarin itself was authorized for the treatment of lymphedema in 1993, but in 1996 the Australian regulatory authorities suspended the drug due to the apparition of ten cases of hepatotoxicity with two fatalities.
In 2004, the European Food Safety Authority (EFSA) concluded that the carcinogenic effect was not caused by a genotoxic mechanism, and a tolerable daily intake (TDI) of 0.1 mg coumarin/kg body weight, based on a no observed adverse effect level (NOAEL) for liver toxicity in a 2-year dog study, was established. Based on new available toxicity data, EFSA re-evaluated coumarin in 2008. It was then concluded to maintain the TDI of 0.1 mg coumarin/kg bw allocated in the 2004 opinion.
EFSA maintained this TDI in 2008, with a concession that an exposure of 0.3 mg/kg bw for up to two weeks is not of safety concern.
Around 40% of adults and 43% of children are exposed to coumarin through their diet, mainly via the consumption of condiments (herbs, spices), sauces, pastries, cakes, and sweet biscuits. French people exposed to coumarin can reach up to 20% of this TDI, without including the consumption of food supplements.
Coumarin is an effective treatment for primary lymphoedema, as well as lymphoedema related to breast cancer radiotherapy or surgery. However, its clinical use is limited in several countries due to the possible occurrence of hepatotoxicity, mainly in the form of mild to moderate transaminase elevation. It is worth noting that only a few cases of severe hepatotoxicity have been described in the literature, with no reported cases of liver failure.
Based on available data, coumarin-induced hepatotoxicity is restricted to a small subset of patients, probably due to the activation in these individuals of alternative metabolic pathways involving specific CYP450 isoforms.
A relationship between coumarin dose and hepatotoxicity has not been clearly demonstrated. Indeed, the time to onset of hepatotoxicity varied from 1 to 6 months. In the Mayo Clinic lymphedema trial, coumarin resulted in serologic evidence of liver toxicity in 6 percent of the women. An older estimate from Casley-Smith suggested only oral coumarin may cause idiosyncratic hepatitis (3 per 1,000).
The French agency ANSES advises people with a history of liver disease to avoid consumption of cinnamon-rich foods and food supplements containing coumarin.
It is known from animal experiments that coumarin can cause liver toxicity and it is considered a carcinogen in mice and possibly also in rats via the oral route. However, coumarin was at first suspected to have genotoxic and carcinogenic effects in humans, but new toxicological data have shown it to be nongenotoxic, making it possible to define a tolerable daily intake. The mechanistic basis for this species difference is well characterized: most humans possess a major pathway for the metabolism of coumarin (the 7-hydroxycoumarin pathway) that differs from that in rats (the 3,4-coumarin epoxidation pathway), in which a reactive epoxide is formed. The 3,4-coumarin epoxide route has been linked to the hepatotoxicity and carcinogenic effects of coumarin observed in long-term studies in rats and mice.
Detoxification of coumarin through 7-hydroxylation may vary among individuals due to genetic polymorphisms in the CYP2A6 enzyme. This pharmacogenomic variability is a key reason why a subset of individuals exposed to similar coumarin doses may develop hepatotoxicity while the majority do not. Pharmacokinetic data suggest a low or negligible concern regarding coumarin-induced hepatotoxicity in humans exposed to an average intake from foods.
Due to its contact allergic properties, coumarin is legally regulated in Regulation (EC) No. 1223/2009 (EU Cosmetics Regulation). The presence of coumarin in cosmetic products must be indicated in the list of ingredients in addition to the indication of perfume or aroma mixtures, from 0.01% in products that remain on the skin or from 0.001% in products that are washed off after application. Australian regulatory authorities imposed a limit of maximum 0.001% coumarin in topical cosmetics, which is considered safe, with a maximum estimated exposure of below 0.02 mg/kg.
The French food safety agency ANSES assessed the risks associated with the coumarin content of certain plants when consumed in food supplements. Coumarin is a natural aromatic compound found in certain plants such as cinnamon. High-dose cinnamon supplements — particularly those made from cassia species — can deliver coumarin intakes well in excess of the EFSA TDI. These reports suggest that deviation from the EFSA established ADI of 0.1 mg/kg bw has the potential to cause hepatotoxicity.
Coumarin as an additive or as a constituent of tonka beans or tonka extracts is banned from food in the United States due to its potentially adverse side effects.
Health conditions that Coumarin may help support.
Coumarin (5,6-benzo-alpha-pyrone), a natural compound found in sweet clover and other plants, has been evaluated in approximately 50 clinical trials for lymphedema. A comprehensive PubMed review by Casley-Smith covering these trials found oral benzopyrones including coumarin reduced lymphedema by a mean of 55% annually across pooled studies. Coumarin increases macrophage numbers in edematous tissue, promoting proteolysis of excess protein and reducing high-protein edema characteristic of lymphedema.
Body systems that Coumarin may help support.
Go back